It is a feasible approach to compare the cancer-proliferative character of adipose tissue, differentiated adipocytes, and SVF cells and to compare them to a nonadipogenic control. Although the present study certainly enriches our knowledge of the carcinogenicity of fat, we want to address one major concern in the ongoing debate of fat grafting and carcinogenicity. The authors correctly state: "from a clinical point of view, the oncological role of the transplanted adipose tissue in promoting local recurrence has not yet been clarified."
1 A great number of in vitro studies and animal experiments have provided an undeniably strong body of evidence for a potential carcinogenic effect of whole adipose tissue, adipocytes, and SVF cells including adipocyte-derived stem cells (ASC). 3 These observations have naturally led to uncertainty and a sensitization of our perception towards fat grafting, which gained respectable popularity as an almost omnipotent tool in plastic surgery. However, the uncertainties are perpetuated by the fact that in the midst of the accumulation of convincing experimental evidence, clinical data largely do not confirm an increased risk of carcinogenicity, metastatic spread, and recurrence in patients after autologous fat grafting. The question of the missing link between experimental and clinical studies remains unanswered.
One decisive reason for the discrepancies is found in the experimental design. Most experimental studies so far focused on the proliferation of different cancer cells, mostly breast-cancer cell lines, when cocultured or co-injected with adipose tissue or cells fractioned from adipose tissue. Although the majority of these types of studies surely reveal an important finding (that adipose tissue and its cell fractions in fact facilitate tumor growth), their informative value regarding tumor progression via fat grafting appears to be limited. Cancer cells are embedded in tumor stroma, which in the case of breast cancer, in particular, predominantly consists of adipose tissue. Therefore, showing a tumor proliferative effect of adipose tissue on cancer cells does not specifically address the problem of fat grafting on cancer development. It merely shows the effect of adipose tissue including physiological tumor stroma on carcinogenesis, but not a carcinogenic risk of the fat grafting procedure per se.
At this point in the research, an extension of experimental approaches is of pivotal importance. Apart from exploration of mechanisms in obesity and tumor-stroma-related carcinogenesis, which are, in all respects, relevant topics in the broad field of cancer research, the main focus of plastic surgeons lies in the concrete investigation of fat grafting on cancer development. What is the rationale to hypothesize that adipose tissue transferred from one part of the body to the other induces cancer and cancer recurrence when the cancer cells are embedded in fat tissue to begin with? Do lipoaspirates differ from the adipose tissue that naturally surrounds the local cancer cells caused by the manipulation lipoaspirates undergo during the harvest, processing, and injection steps?
Furthermore, more intense efforts are desirable to unravel underlying mechanisms in carcinogenesis, find new potential therapy targets, and encourage translational strategies for the future. For instance, Eterno et al have identified c-Met, also known as hepatocyte growth factor receptor (HGFR), as a marker to predict the risk of breast-cancer recurrence for patients undergoing fat grafting. 4 In an elaborate study, the authors have shown that a crosstalk between HGFR and its ligand hepatocyte growth factor (HGF) promotes tumor-cell migration, self-renewal, and expression of specific genes found in metastatic cancers. The authors also co-injected fluorescence-labeled ASCs/breast cancer cell lines in mice, and found that ASCs enhance angiogenesis by recruiting endothelial progenitor cells and by upregulation of vascular endothelial growth factor (VEGF) in cancer cells. We have reported earlier that lipoaspirates also contain significant amounts of growth factors, including VEGF. 5 Thus, potential involvement of the angiogenic axis of lipoaspirates in carcinogenesis may be a topic worthy of more-detailed investigation.
Finally, the carcinogenicity of fat grafts must be examined in appropriate animal models. Animal models have been established for the investigation of adipose tissue in pathologies (eg, high-fat-diet mice for diabetes and obesity-related questions). But there also are a line of breast-cancer models available that may be suitable for studies regarding carcinogenicity of fat grafts. 6 More animal models are continuously developed to recapitulate the ongoing processes more sufficiently. Kocatürk and Versteeg proposed that the injection of breast cancer cells into the mammary fat pads of mice better reflects the tumor microenvironment and allows a greater understanding of cancerous mechanisms, just to mention one possible idea. 7 In conclusion, the experimental investigation of carcinogenic effects of fat grafting has to advance to the next step. Results of preceding studies, including the present article of Massa et al, have shown that adipose tissue promotes cancer. Now, more specific experimental designs, closer examination of potential tumor mechanisms, and the utilization of appropriate animal models have to follow in order to adequately address the question of a potential carcinogenic of fat grafting. Until a scientifically sound, comprehensive consensus is reached, we agree with the authors to select patients with utmost caution and perform a careful follow-up.
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